{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:34:44Z","timestamp":1793406884534,"version":"4.5.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To review the key updates in the 2024 KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease (CKD) and highlight the essential role of pharmacists in implementing these recommendations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>The updated guideline introduces significant changes in CKD management, including the use of validated equations for estimating glomerular filtration rate (GFR) for drug dosing, with incorporation of serum cystatin C into GFR estimates for specific patient populations, and an emphasis on a comprehensive approach to delay disease progression. The guideline recommends sodium-glucose cotransporter 2 inhibitor (SGLT2i) therapy for kidney disease with proteinuria, with or without diabetes, renin-angiotensin-aldosterone system inhibitors (RAASi) blood pressure control and proteinuria management, and statins to reduce the risk of atherosclerotic cardiovascular disease. New evidence supports the use of finerenone in patients with type 2 diabetes and CKD, and GLP-1 receptor agonists for their kidney-protective effects. The guidelines also emphasize the importance of nephrotoxin stewardship and prevention of acute kidney injury through patient education on sick day medication management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pharmacists play a crucial role in implementing these updated guidelines through comprehensive medication management, nephrotoxin stewardship, drug dosing adjustments, and patient education. Their involvement in interprofessional care teams is essential for optimizing health outcomes in patients with CKD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajhp\/zxaf044","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T07:31:22Z","timestamp":1740641482000},"page":"660-671","source":"Crossref","is-referenced-by-count":53,"title":["KDIGO 2024 clinical practice guideline on evaluation and management of chronic kidney disease: A primer on what pharmacists need to know"],"prefix":"10.1093","volume":"82","author":[{"given":"Linda","family":"Awdishu","sequence":"first","affiliation":[{"name":"Division of Clinical Pharmacy, University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences , La Jolla, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Maxson","sequence":"additional","affiliation":[{"name":"Harrison College of Pharmacy, Auburn University , Auburn, AL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea","family":"Gratt","sequence":"additional","affiliation":[{"name":"CVS Pharmacy, Inc. , San Diego, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Rubenzik","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University of California, San Diego School of Medicine , La Jolla, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Battistella","sequence":"additional","affiliation":[{"name":"Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada, and University Health Network , Toronto, ON ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,8]]},"reference":[{"issue":"4S","key":"2025061121162795000_CIT0001","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes CKD Work Group","year":"2024","journal-title":"Kidney Int"},{"issue":"11","key":"2025061121162795000_CIT0002","doi-asserted-by":"publisher","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","article-title":"Evaluation and management of chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2012 clinical practice guideline","volume":"158","author":"Stevens","year":"2013","journal-title":"Ann Intern Med"},{"issue":"19","key":"2025061121162795000_CIT0003","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin c-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"2025061121162795000_CIT0004","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1056\/NEJMoa2203769","article-title":"Cystatin C-based equation to estimate GFR without the inclusion of race and sex","volume":"388","author":"Pottel","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"2025061121162795000_CIT0005","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1056\/NEJMms2029562","article-title":"Race and genetic ancestry in medicine \u2014 a time for reckoning with racism","volume":"384","author":"Borrell","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"2025061121162795000_CIT0006","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1053\/j.ajkd.2021.03.008","article-title":"Reassessing the inclusion of race in diagnosing kidney diseases: an interim report from the NKF-ASN task force","volume":"78","author":"Delgado","year":"2021","journal-title":"Am J Kidney Dis"},{"issue":"3S","key":"2025061121162795000_CIT0007","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2020.11.003","article-title":"KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease","volume":"99","author":"Kidney Disease: Improving Global Outcomes Blood Pressure Work G","year":"2021","journal-title":"Kidney Int"},{"issue":"5S","key":"2025061121162795000_CIT0008","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","author":"Kidney Disease: Improving Global Outcomes Diabetes Work G","year":"2022","journal-title":"Kidney Int"},{"issue":"6823","key":"2025061121162795000_CIT0009","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1136\/bmj.304.6823.339","article-title":"Renal protective effect of enalapril in diabetic nephropathy","volume":"304","author":"Bjorck","year":"1992","journal-title":"BMJ"},{"issue":"3","key":"2025061121162795000_CIT0010","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.kint.2016.09.038","article-title":"Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes","volume":"91","author":"Clase","year":"2017","journal-title":"Kidney Int"},{"issue":"4","key":"2025061121162795000_CIT0011","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/ejhf.2471","article-title":"Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology","volume":"24","author":"Mullens","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"2025061121162795000_CIT0012","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1053\/j.ajkd.2022.01.002","article-title":"Hyperkalemia-related discontinuation of renin-angiotensin-aldosterone system inhibitors and clinical outcomes in ckd: a population-based cohort study","volume":"80","author":"Leon","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"22","key":"2025061121162795000_CIT0013","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1056\/NEJMoa2210639","article-title":"Renin-angiotensin system inhibition in advanced chronic kidney disease","volume":"387","author":"Bhandari","year":"2022","journal-title":"N Engl J Med"},{"issue":"7","key":"2025061121162795000_CIT0014","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"2025061121162795000_CIT0015","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"22","key":"2025061121162795000_CIT0016","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"15","key":"2025061121162795000_CIT0017","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"2025061121162795000_CIT0018","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"The","year":"2023","journal-title":"N Engl J Med"},{"issue":"7","key":"2025061121162795000_CIT0019","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/S2213-8587(20)30162-5","article-title":"Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial","volume":"8","author":"Cherney","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"2025061121162795000_CIT0020","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1111\/dom.13820","article-title":"Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: a population-based study of older women and men with diabetes","volume":"21","author":"Lega","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"2025061121162795000_CIT0021","article-title":"Efficacy, mechanisms and safety of SGLT2 inhibitors in kidney transplant recipients (INFINITI2019)","volume-title":"ClinicalTrials.gov","author":"University Health Network, Toronto"},{"key":"2025061121162795000_CIT0022","article-title":"SGLT2 inhibition in hemodialysis (DAPA-HD)","volume-title":"ClinicalTrials.gov","author":"Medical University of Vienna"},{"issue":"23","key":"2025061121162795000_CIT0023","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"2025061121162795000_CIT0024","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"2025061121162795000_CIT0025","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"issue":"11","key":"2025061121162795000_CIT0026","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s11886-020-01399-7","article-title":"Mineralocorticoid receptor antagonists: a comprehensive review of finerenone","volume":"22","author":"Rico-Mesa","year":"2020","journal-title":"Curr Cardiol Rep"},{"issue":"4","key":"2025061121162795000_CIT0027","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1093\/ndt\/gfac198","article-title":"Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE)","volume":"38","author":"Green","year":"2023","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"2025061121162795000_CIT0028","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"2025061121162795000_CIT0029","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03133-0","article-title":"Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial","author":"Mann","year":"2024","journal-title":"Nat Med"},{"issue":"4","key":"2025061121162795000_CIT0030","doi-asserted-by":"publisher","first-page":"553","DOI":"10.2337\/cd22-0110","article-title":"Perspectives on chronic kidney disease with type 2 diabetes and risk management: practical viewpoints and a paradigm shift using a pillar approach","volume":"41","author":"Morales","year":"2023","journal-title":"Clin Diabetes"},{"issue":"1","key":"2025061121162795000_CIT0031","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2021-001585","article-title":"Four pillars of heart failure: contemporary pharmacological therapy for heart failure with reduced ejection fraction","volume":"8","author":"Straw","year":"2021","journal-title":"Open Heart"},{"issue":"2","key":"2025061121162795000_CIT0032","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.ccc.2020.11.002","article-title":"Nephrotoxin stewardship","volume":"37","author":"Kane-Gill","year":"2021","journal-title":"Crit Care Clin"},{"key":"2025061121162795000_CIT0033","author":"Administration FaD"},{"issue":"8","key":"2025061121162795000_CIT0034","doi-asserted-by":"publisher","DOI":"10.3390\/jcm7080211","article-title":"Use of estimating equations for dosing antimicrobials in patients with acute kidney injury not receiving renal replacement therapy","volume":"7","author":"Awdishu","year":"2018","journal-title":"J Clin Med"},{"issue":"9","key":"2025061121162795000_CIT0035","doi-asserted-by":"publisher","first-page":"100491","DOI":"10.1016\/j.xkme.2022.100491","article-title":"Sick day medication guidance for people with diabetes, kidney disease, or cardiovascular disease: a systematic scoping review","volume":"4","author":"Watson","year":"2022","journal-title":"Kidney Med"},{"issue":"3","key":"2025061121162795000_CIT0036","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy7030083","article-title":"A primer on quality assurance and performance improvement for interprofessional chronic kidney disease care: a path to Joint Commission certification","volume":"7","author":"Awdishu","year":"2019","journal-title":"Pharmacy (Basel)"},{"issue":"4","key":"2025061121162795000_CIT0037","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy7040142","article-title":"Advancing pharmacist collaborative care within academic health systems","volume":"7","author":"Awdishu","year":"2019","journal-title":"Pharmacy (Basel)"},{"issue":"5","key":"2025061121162795000_CIT0038","doi-asserted-by":"publisher","first-page":"922","DOI":"10.34067\/KID.0007182021","article-title":"Impact of medication reconciliation by a dialysis pharmacist","volume":"3","author":"Dyer","year":"2022","journal-title":"Kidney360"},{"issue":"4","key":"2025061121162795000_CIT0039","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.amjmed.2020.12.008","article-title":"Assessing the impact of comprehensive medication management on achievement of the quadruple aim","volume":"134","author":"McFarland","year":"2021","journal-title":"Am J Med"},{"issue":"2","key":"2025061121162795000_CIT0040","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1331\/JAPhA.2008.07108","article-title":"Clinical and economic outcomes of medication therapy management services: the Minnesota experience","volume":"48","author":"Isetts","year":"2008","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"5","key":"2025061121162795000_CIT0041","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19052781","article-title":"Healthcare utilisation and clinical outcomes in older cardiovascular patients receiving comprehensive medication management services: a nonrandomised clinical study","volume":"19","author":"Brajkovic","year":"2022","journal-title":"Int J Environ Res Public Health"},{"issue":"2","key":"2025061121162795000_CIT0042","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/jac5.1177","article-title":"Optimizing the primary care clinical pharmacy specialist: increasing patient access and quality of care within the Veterans Health Administration","volume":"3","author":"Mcfarland","year":"2020","journal-title":"J Am Coll Clin Pharm"},{"issue":"6","key":"2025061121162795000_CIT0043","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1002\/jac5.1254","article-title":"Incorporating social determinants of health into comprehensive medication management: insights from the field","volume":"3","author":"Pestka","year":"2020","journal-title":"J Am Coll Clin Pharm"},{"issue":"11","key":"2025061121162795000_CIT0044","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/jac5.1700","article-title":"Determining best practices to delivering comprehensive medication management in practices with patients with chronic kidney disease: a qualitative study","volume":"5","author":"Pestka","year":"2022","journal-title":"J Am Coll Clin Pharm"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxaf044\/62883537\/zxaf044.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/82\/12\/660\/62883537\/zxaf044.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/82\/12\/660\/62883537\/zxaf044.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T21:16:32Z","timestamp":1749676592000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/82\/12\/660\/8107680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,8]]},"references-count":44,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,4,8]]},"published-print":{"date-parts":[[2025,6,11]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxaf044","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6,15]]},"published":{"date-parts":[[2025,4,8]]}}}